| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
BTK/PD-1 blockade for treatment of Richter's transformation
|
Tang, Pek Sang
|
|
2019
|
6 |
2 |
p. e59-e60
|
artikel
|
| 2 |
GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study
|
Bonifazi, Francesca
|
|
2019
|
6 |
2 |
p. e89-e99
|
artikel
|
| 3 |
In-vivo T-cell depletion: burden of morbidity versus survival
|
Eapen, Mary
|
|
2019
|
6 |
2 |
p. e63-e64
|
artikel
|
| 4 |
Is venous thromboembolism a problem in patients with cancer in palliative care?
|
Sandset, Per Morten
|
|
2019
|
6 |
2 |
p. e61-e62
|
artikel
|
| 5 |
Novel pathway inhibitors for the treatment of chronic lymphocytic leukaemia
|
Molica, Stefano
|
|
2019
|
6 |
2 |
p. e65-e66
|
artikel
|
| 6 |
Prevalence, symptom burden, and natural history of deep vein thrombosis in people with advanced cancer in specialist palliative care units (HIDDen): a prospective longitudinal observational study
|
White, Clare
|
|
2019
|
6 |
2 |
p. e79-e88
|
artikel
|
| 7 |
Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study
|
Younes, Anas
|
|
2019
|
6 |
2 |
p. e67-e78
|
artikel
|
| 8 |
Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial
|
Nastoupil, Loretta J
|
|
2019
|
6 |
2 |
p. e100-e109
|
artikel
|
| 9 |
To treat, or not to treat: the dilemma for pregnant women
|
The Lancet Haematology,
|
|
2019
|
6 |
2 |
p. e58
|
artikel
|
Tijdschrift beschrijving